Strategic International Session3(JSGS・JSGE・JSH)
Sat. November 4th   9:00 - 11:30   Room 9: Portopia Hotel Main Building Kairaku 3
Challenge for living donor liver transplantation for non-resectable colorectal liver metastases
Ken Fukumitsu1,2, Takashi Ito1, Etsuro Hatano1
1Department of Surgery, Kyoto University, 2Department of Surgery, Kyoto Katsura Hospital
In colorectal cancer, there are cases in which metastasis is localized to the liver but unresectable. Recently, the study group in Norway reported that liver transplantation for non-resectable colorectal liver metastases resulted in a 5-year overall survival of 83%, and 18 clinical trials have been conducted around the world currently. Japan should not be left behind in this global trend, and our purpose is to bring this novel treatment options to Japanese patients as soon as possible.
This clinical study will be conducted as an advanced medical treatment, with the goal of being covered by insurance. This study is a multicenter study with 11 institutions, and the Central Judgment Committee make decisions regarding unresectability and the indication for liver transplantation. The eligibility criteria are that metastases must be confined to the liver, but patients with an evaluation as Progressive Disease during chemotherapy is excluded. The expected enrollment number of patients is 23, the study period is 9 years, and the primary endpoint is the 3-year overall survival. The study has already been approved by the Institutional Review Board in December 2022.
Liver transplantation is a novel treatment option for non-resectable colorectal liver metastases. The significance and details of this study will be presented.
Index Term 1: living donor liver transplantation
Index Term 2: non-resectable colorectal liver metastases
Page Top